We provide the first evidence that the clinically proven inhibitor of LSD1 iadademstat can be used to circumvent the challenge of pharmacologically manipulating the epigenetic re-activation of SOX2 that causes a subpopulation of tumor cells to shift towards a CSC state, which has constrained the clinical relevance of SOX2-centered therapeutic strategies in major cancer types such as breast cancer. Here, KDM1A is linked to neoplasm.